Skip to content
OpenCapital
Get started

Dyne Therapeutics, Inc. DYN Payment Of Issuance Costs From Public Offering Of Common Stock

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$3.35B+153%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Reported directly by Dyne Therapeutics, Inc. in its filing.

Tagged under the XBRL concept dyn:PaymentOfIssuanceCostsFromPublicOfferingOfCommonStock.

The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Dyne Therapeutics, Inc.'s payment of issuance costs from public offering of common stock?
Dyne Therapeutics, Inc. (DYN) reported payment of issuance costs from public offering of common stock of $424K in Q1 2026.